These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 23263913)

  • 1. A study of circulating anti-CD25 antibodies in non-small cell lung cancer.
    Ye L; Li X; Sun S; Guan S; Wang M; Guan X; Lee KH; Wei J; Liu B
    Clin Transl Oncol; 2013 Aug; 15(8):633-7. PubMed ID: 23263913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating autoantibody to CD25 may be a potential biomarker for early diagnosis of esophageal squamous cell carcinoma.
    Guan S; Liu B; Zhang C; Lee KH; Sun S; Wei J
    Clin Transl Oncol; 2013 Oct; 15(10):825-9. PubMed ID: 23423807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autoantibodies against p16 protein-derived peptides may be a potential biomarker for non-small cell lung cancer.
    Zhang C; Ye L; Guan S; Jin S; Wang W; Sun S; Lee KH; Wei J; Liu B
    Tumour Biol; 2014 Mar; 35(3):2047-51. PubMed ID: 24122232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alteration of circulating natural autoantibodies to CD25-derived peptide antigens and FOXP3 in non-small cell lung cancer.
    Zhao H; Zhang X; Han Z; Xie W; Yang W; Wei J
    Sci Rep; 2018 Jun; 8(1):9847. PubMed ID: 29959381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of circulating natural antibodies against CD25, MUC1, and VEGFR1 for early diagnosis of non-small cell lung cancer.
    Liu S; Zhang X; Jiang Q; Liang T
    FEBS Open Bio; 2020 Jul; 10(7):1288-1294. PubMed ID: 32392378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased Levels of Circulating Anti-ANXA1 IgG Antibody in Patients with Non-Small Cell Lung Cancer.
    Liang T; Han Z; Zhao H; Zhang X; Wang Y
    Clin Lab; 2018 Jun; 64(6):895-900. PubMed ID: 29945332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are circulating autoantibodies to ABCC3 transporter a potential biomarker for lung cancer?
    Liu L; Liu N; Liu B; Yang Y; Zhang Q; Zhang W; Yu P; Jin Y; Guo J; Guan S; Sun S; Miao L; Wei J
    J Cancer Res Clin Oncol; 2012 Oct; 138(10):1737-42. PubMed ID: 22699933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Change of circulating antibodies against CD25-derived peptide antigen in hepatocellular carcinoma.
    Wang J; Xu Y; Zhao H; Zhang X
    J Cancer Res Ther; 2017; 13(5):813-816. PubMed ID: 29237909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated Circulating CD4
    Hu X; Gu Y; Zhao S; Hua S; Jiang Y
    Cancer Biother Radiopharm; 2019 Jun; 34(5):325-333. PubMed ID: 30925076
    [No Abstract]   [Full Text] [Related]  

  • 10. Study of circulating antibodies against CD25 and FOXP3 in breast cancer.
    Liu T; Song YN; Shi QY; Liu Y; Bai XN; Pang D
    Tumour Biol; 2014 Apr; 35(4):3779-83. PubMed ID: 24347486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disturbed Th17/Treg Balance in Patients with Non-small Cell Lung Cancer.
    Duan MC; Han W; Jin PW; Wei YP; Wei Q; Zhang LM; Li JC
    Inflammation; 2015 Dec; 38(6):2156-65. PubMed ID: 26077695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes of CD4+CD25+FOXP3+ and CD8+CD28- regulatory T cells in non-small cell lung cancer patients undergoing surgery.
    Chen C; Chen D; Zhang Y; Chen Z; Zhu W; Zhang B; Wang Z; Le H
    Int Immunopharmacol; 2014 Feb; 18(2):255-61. PubMed ID: 24345703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Combination of IgA and IgG autoantibodies against Transcriptional Intermediary Factor-1γ contributes to the early diagnosis of Lung Cancer.
    Yu L; Lin X; Zhang L; Wu Q; Zhang S; Chen D; Pan X; Huang Y
    Int J Med Sci; 2020; 17(11):1561-1568. PubMed ID: 32669959
    [No Abstract]   [Full Text] [Related]  

  • 14. Detection of Plasma Antibodies Against CD25-Derived Peptide Antigens in Bladder Cancer.
    Du KL; Ji WT; Jiang QH; Wang Y
    Clin Lab; 2023 May; 69(5):. PubMed ID: 37145070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-p16 autoantibodies may be a useful biomarker for early diagnosis of esophageal cancer.
    Jin Y; Guan S; Liu L; Sun S; Lee KH; Wei J
    Asia Pac J Clin Oncol; 2015 Dec; 11(4):e37-41. PubMed ID: 24811068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD8+CD28- cells and CD4+CD25+ regulatory T cells in the peripheral blood of advanced stage lung cancer patients.
    Karagöz B; Bilgi O; Gümüs M; Erikçi AA; Sayan O; Türken O; Kandemir EG; Oztürk A; Yaylaci M
    Med Oncol; 2010 Mar; 27(1):29-33. PubMed ID: 19148592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between CD4+CD25+ Treg and expression of HIF-1α and Ki-67 in NSCLC patients.
    He LY; Li L; Guo ML; Zhang Y; Zhang HZ
    Eur Rev Med Pharmacol Sci; 2015 Apr; 19(8):1351-5. PubMed ID: 25967708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study of Circulating Natural Antibodies Against CD25 and FOXP3 in Type-2 Diabetes.
    Qiu C; Li C; Wu X; Chen X; Zhang X; Meng Q
    Clin Lab; 2020 Aug; 66(8):. PubMed ID: 32776743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of circulating antibodies to linear peptide antigens derived from ANXA1 and DDX53 in lung cancer.
    Wang W; Guan S; Sun S; Jin Y; Lee KH; Chen Y; Wei J
    Tumour Biol; 2014 May; 35(5):4901-5. PubMed ID: 24453033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigation of circulating antibodies to ANXA1 in breast cancer.
    Huang Y; Zhang C; Chen C; Sun S; Zheng H; Wan S; Meng Q; Chen Y; Wei J
    Tumour Biol; 2015 Feb; 36(2):1233-6. PubMed ID: 25344217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.